1.065USD+3.40%Mkt Cap: 90.24M USDP/E: —Last update: 2026-05-26
Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate …
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap90.24M USD
Enterprise Value74.64M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-49.87M USD
Revenue/Share—
Last Price1.065 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees10
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-3.46
EV/Revenue—
P/S—
P/B-1.02
EPS (TTM)-1.90
EPS (Forward)—
52W Range
0.95009% of range2.210
52W High2.210 USD
52W Low0.9500 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE177.56%
ROA-206.44%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-19.36M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-8.85%
Net Debt478.00K USD
Net Debt/EBITDA-0.02
Balance Sheet
Debt/Equity42.47
Current Ratio0.40
Quick Ratio0.33
Book Value/Sh-1.0190 USD
Cash/Share0.1590 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateNov 11, 2022
Analyst Consensus
Rating—
Target (Mean)10.00 USD
Target Range10.00 USD – 10.00 USD
# Analysts1
Ownership
Shares Out.85.54M
Float21.35M
Insiders6.79%
Institutions13.37%
Short Interest
Short Ratio4.5d
Short % Float3.54%
Short % Out.2.98%
Shares Short835.37K
Short (prev mo.)487.16K
Technical
SMA 501.347 (-21.0%)
SMA 2001.298 (-17.9%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)1.06M
Avg Vol (10d)743.54K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—